Kalaris to Participate at Stifel Ophthalmology Forum
Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will engage in a Fireside Chat on Tuesday, May 27th, 2025, at 8:00 AM ET. A replay of the event will be available on the company's Investor Relations webpage.
Kalaris Therapeutics (NASDAQ: KLRS), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per le malattie retiniche, ha annunciato la sua partecipazione al Stifel 2025 Virtual Ophthalmology Forum. Il management dell'azienda, incluso l'Amministratore Delegato Andrew Oxtoby e il Direttore Medico Matthew Feinsod, parteciperà a una Fireside Chat il martedì 27 maggio 2025, alle 8:00 ET. La registrazione dell'evento sarà disponibile sulla pagina delle Relazioni con gli Investitori dell'azienda.
Kalaris Therapeutics (NASDAQ: KLRS), una compañía biofarmacéutica en etapa clínica enfocada en tratamientos para enfermedades retinianas, anunció su participación en el Stifel 2025 Virtual Ophthalmology Forum. La dirección de la empresa, incluyendo al CEO Andrew Oxtoby y al CMO Matthew Feinsod, participará en una Fireside Chat el martes 27 de mayo de 2025 a las 8:00 AM ET. La repetición del evento estará disponible en la página de Relaciones con Inversionistas de la compañía.
Kalaris Therapeutics (NASDAQ: KLRS)는 망막 질환 치료에 중점을 둔 임상 단계의 생명공학 제약 회사로, Stifel 2025 Virtual Ophthalmology Forum에 참가할 예정임을 발표했습니다. 회사 경영진인 CEO Andrew Oxtoby와 CMO Matthew Feinsod가 2025년 5월 27일 화요일 오전 8시(동부시간)에 Fireside Chat에 참여합니다. 행사 녹화 영상은 회사 투자자 관계 웹페이지에서 다시 볼 수 있습니다.
Kalaris Therapeutics (NASDAQ: KLRS), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies rétiniennes, a annoncé sa participation au Stifel 2025 Virtual Ophthalmology Forum. La direction de l'entreprise, comprenant le PDG Andrew Oxtoby et le Directeur Médical Matthew Feinsod, participera à une discussion informelle (Fireside Chat) le mardi 27 mai 2025 à 8h00 ET. Un replay de l'événement sera disponible sur la page Relations Investisseurs de la société.
Kalaris Therapeutics (NASDAQ: KLRS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Behandlungen von Netzhauterkrankungen, gab seine Teilnahme am Stifel 2025 Virtual Ophthalmology Forum bekannt. Das Management des Unternehmens, darunter CEO Andrew Oxtoby und CMO Matthew Feinsod, wird an einem Fireside Chat am Dienstag, den 27. Mai 2025, um 8:00 Uhr ET teilnehmen. Eine Aufzeichnung der Veranstaltung wird auf der Investor-Relations-Webseite des Unternehmens verfügbar sein.
- None.
- None.
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
Details:
- Type: Fireside Chat
- Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
- Date: Tuesday, May 27th, 2025
- Time: 08:00 am ET
- Location: Webcast
Following the event, a replay will be hosted on Kalaris Therapeutics’ Investor Relations webpage.
About Kalaris
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
FAQ
When is Kalaris Therapeutics (KLRS) presenting at the Stifel Ophthalmology Forum 2025?
Who will represent Kalaris Therapeutics at the Stifel 2025 Ophthalmology Forum?
What type of company is Kalaris Therapeutics (KLRS)?
How can investors access the Kalaris Therapeutics Stifel presentation replay?
